华邦健康(002004) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥2,984,352,397.45, a decrease of 14.28% compared to ¥3,481,328,298.92 in the same period last year[8] - Net profit attributable to shareholders for Q3 2023 was ¥117,780,192.97, down 25.03% from ¥157,107,051.58 year-on-year[8] - The net profit after deducting non-recurring gains and losses was ¥106,595,479.19, reflecting a decline of 25.65% compared to ¥143,372,114.16 in the previous year[8] - Basic earnings per share for Q3 2023 were ¥0.0595, down 25.06% from ¥0.0794 in the same quarter last year[8] - The net profit for the current period is 875,142,530.13, a decrease of 34.7% compared to 1,342,581,873.08 in the previous period[30] - Operating profit for the current period is 1,118,574,829.98, down from 1,818,006,436.61, reflecting a decline of 38.5%[30] - Total comprehensive income for the current period is 931,186,872.20, down from 1,553,326,463.12, representing a decline of 40.0%[30] - The company reported a basic earnings per share of 0.2550, down from 0.3621, reflecting a decrease of 29.5%[30] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥970,589,635.32, a significant drop of 48.61% from ¥1,888,672,141.44[8] - The net cash flow from operating activities decreased by 48.61% to ¥970,589,635.32 compared to ¥1,888,672,141.44 in the previous period, primarily due to a decline in sales scale[16] - The net cash flow from investing activities showed a significant decrease of 1620.00%, amounting to -¥409,598,318.92, attributed to increased long-term asset purchases and a reduction in redeemed financial products[16] - The net cash flow from financing activities increased by 47.90% to -¥464,731,600.04, mainly due to an increase in financing scale during the reporting period[16] - Cash flow from operating activities generated a net amount of 970,589,635.32, compared to 1,888,672,141.44 in the previous period, indicating a decrease of 48.6%[33] - Cash inflow from investment activities is 5,213,786,313.09, down from 6,399,652,310.89, indicating a decline of 18.5%[33] - The company’s cash flow from financing activities totaled 7,274,106,554.18, an increase from 6,965,012,937.74, reflecting a growth of 4.4%[33] - Net cash flow from financing activities improved to -$464,731,600.04 from -$892,058,256.68[36] Assets and Liabilities - Total assets at the end of the reporting period were ¥30,375,904,765.21, an increase of 1.15% from ¥30,024,403,300.33 at the end of the previous year[8] - The total assets amount to ¥30,375,904,765.21, up from ¥30,029,364,092.71, showing growth in the company's asset base[27] - Non-current liabilities increased to ¥3,234,045,121.90 from ¥2,366,822,363.47, suggesting potential leverage for future investments[27] - The company's total liabilities stand at ¥13,611,603,933.92, compared to ¥13,478,456,807.24 in the previous period, indicating a slight increase in financial obligations[27] - Total liabilities increased to $13,478,456,807.24, up by $4,843,642.12[37] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 83,533, with the top ten shareholders holding 18.71% of the shares[17] - Xizang Huibang Technology Co., Ltd. holds 370,449,804 shares, representing 18.71% of the total shares, and has pledged 169,207,000 shares[17] - Zhang Songshan, a natural person, holds 117,095,583 shares, accounting for 5.91% of the total shares, with 57,140,000 shares pledged[17] Operational Metrics - Total operating revenue for the current period is ¥8,853,071,322.91, a decrease of 13.0% from ¥10,180,991,733.93 in the previous period[28] - Total operating costs for the current period are ¥7,857,544,207.71, down from ¥8,815,184,892.05, reflecting a cost reduction strategy[28] - The net profit margin is under pressure due to a decrease in operating revenue and an increase in sales expenses, which reached ¥1,021,485,264.52[28] - Research and development expenses increased to ¥325,832,813.94, compared to ¥286,550,552.75 in the previous period, indicating a focus on innovation[28] Liquidity and Cash Management - The company's cash and cash equivalents decreased from ¥4,186,619,295.37 to ¥3,982,678,887.21, reflecting a decrease in liquidity[21] - The company reported a decrease in cash and cash equivalents, impacting liquidity, with current assets totaling ¥11,192,759,675.35, down from ¥11,554,220,664.68[27] - The ending balance of cash and cash equivalents was $3,088,618,169.40, down from $3,520,862,118.20[36] - The net increase in cash and cash equivalents was $97,297,058.47, a significant decrease from $1,017,905,834.60 in the previous period[36] Accounting and Regulatory Changes - The company plans to adjust its accounting policies in response to new regulations effective from January 1, 2023, impacting deferred tax assets and liabilities[8] - Deferred tax assets increased to $342,078,600.61 from $337,117,808.23 due to the implementation of new accounting standards[37] Impairments and Losses - The company reported a significant impairment loss of ¥874,768.95, primarily due to inventory and fixed asset impairments[16] Audit Status - The company’s third-quarter report was not audited[38]